Cytek Biosciences (NASDAQ: CTKB) revenue
Cytek Biosciences reported revenue of $201.5m for fiscal 2025, 0.5% more than in fiscal 2024 ($200.5m). Since fiscal 2020 its revenue has grown by 117.0%, an average growth of 16.8% a year.
Cytek Biosciences has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $201.5m | +0.5% | −$40.4m | −20.0% |
| 2024 | $200.5m | +3.9% | −$20.5m | −10.2% |
| 2023 | $193.0m | +17.7% | −$27.8m | −14.4% |
| 2022 | $164.0m | +28.2% | −$1.8m | −1.1% |
| 2021 | $128.0m | +37.8% | $9.2m | 7.2% |
| 2020 | $92.8m | — | $13.7m | 14.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cytek Biosciences revenue compared with its sector
By revenue for its latest fiscal year, Cytek Biosciences ranks 247th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Cytek Biosciences, 0.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 245th | Vanda Pharmaceuticals | $216.1m | 8.7% |
| 246th | Establishment Labs | $211.1m | 27.1% |
| 247th | Cytek Biosciences | $201.5m | 0.5% |
| 248th | SI-Bone | $200.9m | 20.2% |
| 249th | Strata Critical Medical | $197.1m | 34.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Cytek Biosciences
- How much revenue did Cytek Biosciences make in fiscal 2025?
- Cytek Biosciences reported revenue of $201.5m for fiscal 2025, compared with $200.5m in fiscal 2024.
- How much has the revenue of Cytek Biosciences grown?
- Between fiscal 2020 and fiscal 2025 it went from $92.8m to $201.5m: 117.0% more, an average growth of 16.8% a year.
- What was the best year for revenue at Cytek Biosciences?
- Of its last 6 fiscal years, fiscal 2025, with $201.5m.
- Where does Cytek Biosciences rank in its sector by revenue?
- It ranks 247th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Cytek Biosciences come from?
- From the annual report (Form 10-K) that Cytek Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cytek Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Cytek Biosciences: the Cytek Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.